Literature DB >> 8084515

Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease.

W A van Gool1, D B Schenk, P A Bolhuis.   

Abstract

Cerebral deposition of amyloid-beta protein (A beta) is central to the pathogenesis of Alzheimer's disease (AD). Increasing age is one of the few definitively established risk factors for this disease. The concentration of A beta was measured in cerebrospinal fluid (CSF) with a sensitive enzyme-linked immunosorbent assay in 18 adult neurological patients free from neurodegenerative disease. CSF A beta increased with age, yielding a significant correlation of 0.84. This observation suggests that increased levels of A beta in CSF may be an index of age-related changes in the processing of the amyloid-beta precursor protein resulting in an increased risk for AD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8084515     DOI: 10.1016/0304-3940(94)90677-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

2.  Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro.

Authors:  Abhay Moghekar; Sneha Rao; Ming Li; Dawn Ruben; Andrew Mammen; Xiaopei Tang; Richard J O'Brien
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

3.  Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons.

Authors:  E Paradis; H Douillard; M Koutroumanis; C Goodyer; A LeBlanc
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

4.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers.

Authors:  S R Hughes; S Goyal; J E Sun; P Gonzalez-DeWhitt; M A Fortes; N G Riedel; S R Sahasrabudhe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 6.  Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?

Authors:  Hyoung-Gon Lee; Rudy J Castellani; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Int J Exp Pathol       Date:  2005-06       Impact factor: 1.925

Review 7.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 8.  Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease.

Authors:  Takaomi C Saido
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2013       Impact factor: 3.493

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.